Specifically, increased CSF IL-6 levels at the time of diagnosis have also been associated to a higher number of relapses and increased disability in RR-MS patients during a 3-year-long follow-up period (Stampanoni Bassi et al., 2018). The gene discussed is IL6; the disease is myeloid sarcoma.